Skip to main content

Ariceum Therapeutics establishes subsidiary in Basel

| News

Ariceum Therapeutics establishes subsidiary in Basel


The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel Area Business & Innovation. Germo Gericke from Novartis was named Chief Medical Officer. He also leads the activities in the Basel Area.

Germo Gericke leads the new subsidiary of Ariceum Therapeutics in Basel (img: Ariceum Therapeutics)

Ariceum Therapeutics has established a subsidiary in Basel. The private biotech company develops radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers. According to a press release, Germo Gericke from Novartis was named Chief Medical Officer.

Ariceum’s CEO Manfred Rüdiger comments, that the aim of opening the new subsidiary in Basel is to expand the team “to build a global development hub for Ariceum”. He adds that Germo Gericke is bringing a wealth of experience in the area of radiopharmaceutical therapy and that he will lead and develop the team for clinical development and operational processes from the new subsidiary in Basel.

Basel attracts talent from all over Europe

The new Chief Medical Officer Germo Gericke is convinced: “Basel is at the heart of the European Life Sciences industry. It offers a well-connected, business-friendly environment and great networking opportunities thanks to the cluster of sector activity in the area.” He added that the city’s central location attracts talent from all over Europe and beyond. “We offer exciting career development opportunities within a modern office space and the scope to benefit from the great living and working environment that Basel provides, and look forward to tapping into Basel Area’s talent pool.”

Gericke is coming from Advanced Accelerator Applications (AAA), a Novartis company that develops radioligand therapies and imaging radioligands for oncology indications. He was Chief Medical Officer and Head of Research and Development. According to a press release, Gericke has built a global R&D organization for radioligand therapies.

Ariceum Therapeutics with headquarters in Berlin was supported in its settlement in Switzerland by Basel Area Business & Innovation.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.